KKR Invests $50 Million in Cohera Medical
10.28.15
This is only gets display when printing
The Firm represented KKR in connection with the announced closing of the first tranche of a $50 million equity financing for Cohera Medical, Inc. (“Cohera Medical”). Cohera Medical will use the funds to launch U.S. commercial sales of TissuGlu, the first synthetic adhesive approved by the FDA for internal use. In addition, the company intends to advance clinical trials for Sylys, an innovative surgical sealant under development for bowel repair with significant market potential.
Cohera Medical is a leading innovator and developer of absorbable surgical adhesives and sealants. The company’s products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use and forms a strong bond between tissue layers.
The Simpson Thacher team included Andrew Smith, Phong Quan and Erika Tang (Corporate); Nancy Mehlman and Devin Heckman (Tax); Tristan Brown, Thomas Asmar and Leah Segall (Executive Compensation and Employee Benefits); Lori Lesser and Michelle Morad (Intellectual Property); Adeeb Fadil and Louise Kruger (Environmental); and Abram Ellis (Regulatory).